Federated Investors Inc. PA held its position in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) during the fourth quarter, Holdings Channel reports. The fund owned 110,000 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Federated Investors Inc. PA’s holdings in Sunesis Pharmaceuticals were worth $398,000 as of its most recent filing with the SEC.
Separately, Great Point Partners LLC acquired a new position in Sunesis Pharmaceuticals during the third quarter worth $4,648,000. Institutional investors and hedge funds own 34.30% of the company’s stock.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) opened at 4.11 on Friday. The firm has a 50 day moving average of $4.16 and a 200-day moving average of $4.09. Sunesis Pharmaceuticals, Inc. has a 1-year low of $2.64 and a 1-year high of $6.30. The company’s market capitalization is $86.00 million.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings results on Thursday, March 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.01. Sunesis Pharmaceuticals had a negative net margin of 1,623.12% and a negative return on equity of 806.43%. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.60 million. During the same quarter in the prior year, the company earned ($0.91) earnings per share. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. On average, equities research analysts anticipate that Sunesis Pharmaceuticals, Inc. will post ($2.48) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Web Breaking News and is the sole property of of Web Breaking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at http://www.webbreakingnews.com/2017/03/26/sunesis-pharmaceuticals-inc-snss-stake-maintained-by-federated-investors-inc-pa.html.
SNSS has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 5th. Cantor Fitzgerald lowered shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, December 28th.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Want to see what other hedge funds are holding SNSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.